Stivarga (regorafenib) — CareFirst (Caremark)
Central nervous system (CNS) cancers – glioblastoma or high-grade glioma
Initial criteria
- Requested for treatment of recurrent or progressive glioblastoma or high-grade glioma as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months